Main Menu

News

/News

Congratulations to Dr. Frits van Rhee on his newest publication

Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, "A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease". Be sure to check it out! Read here on Onctotarget

August 5th, 2015|News, Uncategorized|

Important Lessons Learned from the Measles Virus in Multiple Myeloma

Full MCRI Show: Important Lessons Learned from the Measles Virus in Multiple Myeloma and the Next Step to Advance the Fascinating Viro Therapy with Dr. Frits van Rhee and Dr. Stephen Russell The measles virus grabbed media attention with one patient’s amazing outcome. Dr. Russell and Dr. van Rhee hope to expand those results into [...]

June 9th, 2015|News, Uncategorized|

Celgene Gift to UAMS Myeloma Institute for Bart Barlogie Center for Molecular Diagnostics

The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) has received a generous gift from Celgene Corporation to benefit patients with multiple myeloma through the creation of The Bart Barlogie Center for Molecular Diagnostics and the establishment of the Celgene Distinguished Endowed Chair in Molecular Therapeutics. “This is an exciting, new collaboration [...]

March 2nd, 2015|News, Uncategorized|